Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
26 participants
INTERVENTIONAL
2017-11-01
2019-12-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Platelet-rich Plasma in Treatment of Melasma
NCT03674203
Efficacy of Intralesional PRP +/- Topical Silymarin in the Treatment of Melasma
NCT05626881
Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma
NCT04765930
Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma
NCT05884151
Platelet-rich Plasma With Topical Retinoids Versus Topical Retinoids Alone in Acne Vulgaris
NCT06281782
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
transforming growth factor -β1 decreases melanogenesis via delayed extracellular signal-regulated kinase activation. The regression of melasma in a 27-years-old woman after injecting platelet rich plasma for skin rejuvenation was observed, but controlled clinical trials are still lacking to confirm this preliminary observation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Platelet rich plasma
intradermal injection of 5 ml of autologous platelet rich plasma in the lesional skin of the face of 20 melasma patients every 4 weeks for 3 times
Platelet rich plasma
10 ml of blood will be drawn from the patients on an anticoagulant then it will be centrifuged to get platelet rich plasma that will be injected in the melasma lesions of the patients after its activation with calcium chloride.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Platelet rich plasma
10 ml of blood will be drawn from the patients on an anticoagulant then it will be centrifuged to get platelet rich plasma that will be injected in the melasma lesions of the patients after its activation with calcium chloride.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnant females and females on oral contraceptive pills.
* Patients with a history of hypertrophic scars or keloids.
* Patients with recurrent herpes infection or with present cutaneous infection and those with facial cancer.
* Patients with blood disorders and platelet abnormalities and chronic liver disease.
* Patients using systemic chemotherapy, anticoagulation therapy and antiplatelet agents.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
A Ghazally
principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alaa H Ghazally, MD
Role: PRINCIPAL_INVESTIGATOR
Assiut University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assiut university hospitals
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol. 1995 Dec;131(12):1453-7. doi: 10.1001/archderm.131.12.1453.
Cayirli M, Caliskan E, Acikgoz G, Erbil AH, Erturk G. Regression of melasma with platelet-rich plasma treatment. Ann Dermatol. 2014 Jun;26(3):401-2. doi: 10.5021/ad.2014.26.3.401. Epub 2014 Jun 12. No abstract available.
Kim DS, Park SH, Park KC. Transforming growth factor-beta1 decreases melanin synthesis via delayed extracellular signal-regulated kinase activation. Int J Biochem Cell Biol. 2004 Aug;36(8):1482-91. doi: 10.1016/j.biocel.2003.10.023.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ETEPRPM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.